Lupin receives US FDA approval for Glycerol Phenylbutyrate oral liquid
Global pharma major Lupin announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.
Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, is bioequivalent to the reference listed drug (RLD), Ravicti Oral Liquid, 1.1 grams per mL, of Horizon Therapeutics US Holding LLC. It is indicated for chronic management of patients with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
The product sales for Glycerol Phenylbutyrate Oral Liquid (RLD Ravicti) were USD 337 million for the year ended December 2025. (IQVIA MAT DEC 2025).
The post Lupin receives US FDA approval for Glycerol Phenylbutyrate oral liquid appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
